Outcomes of a mandatory non-medical switch of infliximab to a biosimilar for inflammatory bowel disease in British Columbia, Canada.

Thomas Tam HoangJacqueline ReidCherry GalorportBrian BresslerYvette LeungGreg Rosenfeld

Published in: Journal of the Canadian Association of Gastroenterology (2024)

Non-medical biosimilar switch of infliximab demonstrates similar clinical outcomes compared to originator molecule continuation for therapy of IBD. These data support the safety and efficacy of non-medical infliximab switching in IBD patients.

Keyphrases

ulcerative colitis
healthcare
end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
prognostic factors
peritoneal dialysis
type diabetes
big data
stem cells
adipose tissue
patient reported outcomes
weight loss
bone marrow
insulin resistance
glycemic control